Clinical Trial Update: Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating interleukin-2 with sargramostim after chemotherapy for stage III/IV melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Leukine (sargramostim)
• Proleukin (aldesleukin)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Melanoma (Skin) | Phase 2 | Status: WITHDRAWN